The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.
Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.
The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.
The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 222.16 Million |
| Market Size by 2031 | US$ 387.38 Million |
| CAGR (2023 - 2031) | 7.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Type
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Pharmacokinetics Services Market is valued at US$ 222.16 Million in 2023, it is projected to reach US$ 387.38 Million by 2031.
As per our report Europe Pharmacokinetics Services Market, the market size is valued at US$ 222.16 Million in 2023, projecting it to reach US$ 387.38 Million by 2031. This translates to a CAGR of approximately 7.2% during the forecast period.
The Europe Pharmacokinetics Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Pharmacokinetics Services Market report:
The Europe Pharmacokinetics Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Pharmacokinetics Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Pharmacokinetics Services Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Pharmacokinetics Services Market
